PR86510

BEIJING, Nov. 10, 2020 /PRNewswire=KYODO JBN/ --

Insilico Medicine, a leader in deep generative reinforcement learning for

target discovery, small molecule generation, and prediction of clinical trial

outcomes, today announced that it entered into a multi-target drug discovery

agreement with Janssen Pharmaceutica N.V. (Janssen), one of the Janssen

Pharmaceutical Companies of Johnson & Johnson. The collaboration was

facilitated by Johnson & Johnson Innovation LLC.

Photo - https://mma.prnewswire.com/media/1330157/Insilico_Medicine_and_Janssen.jpg 

Under the terms of the agreement, Insilico Medicine will design small molecule

hits with the defined properties for several targets nominated by Janssen and

to receive upfront and milestone payments. Insilico Medicine will demonstrate

the discovery process and detailed platform capabilities.

Since 2015 Insilico Medicine pioneered the field of generative adversarial

networks and reinforcement learning for generative chemistry and generative

biology and published multiple research publications and patents in the area

including proof-of-concept studies with experimental validation. In 2020 it

unveiled the Chemistry42 (https://c212.net/c/link/?t=0&l=en&o=2975293-1&h=3526638674&u=https%3A%2F%2Finsilico.com%2Fchemistry42&a=Chemistry42 )

generative chemistry operating system and made first on-site deployments with

the big pharmaceutical companies and drug discovery partnerships.

"We are very happy to collaborate with Janssen, one of the leading and most

innovative companies in the field of drug discovery. Since 2019 Insilico

Medicine has been a resident of Johnson & Johnson Innovation – JLABS which

facilitated closer communication with the scientists at Janssen and other

companies in the ecosystem and we see this collaboration as a "graduation" from

JLABS", said Alex Zhavoronkov, PhD, founder, and CEO of Insilico Medicine.

About Insilico Medicine

Insilico Medicine develops software that leverages generative models,

reinforcement learning (RL), and other modern machine learning techniques for

the generation of new molecular structures with specific properties. Insilico

Medicine also develops software for the generation of synthetic biological

data, target identification, and the prediction of clinical trials outcomes.

The company integrates two business models; providing AI-powered drug discovery

services and software through its Pharma.AI platform (www.insilico.com/platform/ )

and developing its own pipeline of preclinical programs. The preclinical program is

the result of pursuing novel drug targets and novel molecules discovered through

its platforms. Since its inception in 2014, Insilico Medicine has raised over $52 million

and received multiple industry awards. Insilico Medicine has also published over

100 peer-reviewed papers and has applied for over 25 patents. Website http://insilico.com/ 

Contact: ai@insilico.com

SOURCE  Insilico Medicine Hong Kong Limited